Bernard Ng

Bernard Ng

Auto-generated profile, based on publicly available information

Bernard Ng

Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, United States

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2008 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
AGAraceli Garcia-Gonzalez
Araceli Garcia-Gonzalez
MRMarsha Richardson
Marsha Richardson
MPMaria Garcia Popa-Lisseanu
Maria Garcia Popa-Lisseanu
VCVanessa Cox
Vanessa Cox
MKMichael A. Kallen
Michael A. Kallen
MSMaria E. Suarez-Almazor
Maria E. Suarez-Almazor

1 December 2004 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
BNBernard Ng
Bernard Ng
FYFan Yang
Fan Yang
DHDavid P. Huston
David P. Huston
YYYan Yan
Yan Yan
YYYu Yang
Yu Yang
XYXiao-Feng Yang
Xiao-Feng Yang

23 May 2012 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
BNBernard Ng
Bernard Ng
FAFawad Aslam
Fawad Aslam
NPNancy J. Petersen
Nancy J. Petersen
HYHong‐Jen Yu
Hong‐Jen Yu
MSMaria E. Suarez‐Almazor
Maria E. Suarez‐Almazor
Objective: The accuracy of the diagnosis is vital when administrative databases are used for pharmacoepidemiologic and outcome studies. Data pertaining to the utility of databases for rheumatoid arthritis (RA) are sparse and variable. We assessed the utility of various diagnostic algorithms to identify RA patients within the Veterans Health Administration (VHA) databases.Methods: Using the International Classification of Diseases, Ninth Revision code for RA at 2 visits at least 6 months apart, we identified 1,779 patients between October 1, 1998 and September 30, 2009 in our local Veterans Affairs Medical Center (VAMC) administrative database. Disease‐modifying antirheumatic drug (DMARD) use was ascertained from the pharmacy database. Cases were analyzed based on DMARD therapy and RA codes at clinic visits. A total of 543 patients' medical records, selected by stratification and random selection on the basis of their visits, were reviewed to ascertain the clinicians' diagnoses and clinical criteria documentation. Positive predictive values (PPVs) were calculated for various database case identification algorithms using diagnosis of RA by medical record review as the gold standard.Results: The PPV for identification of RA with 2 RA codes 6 months apart was 30.9%. Addition of DMARD therapy increased the PPV to 60.4%. The PPV further increased to 91.4% when having an RA code at the last VAMC rheumatology clinic visit criterion was added. An algorithm using only 2 administrative RA codes 6 months apart had a low PPV for correctly identifying patients with RA in the VHA database.Conclusion: Including DMARD therapy and requiring an RA code at the last visit with a rheumatologist increased the performance of the data extraction algorithm.

5 April 2013 in BMJ Open
Verified
Journal Article
Open access
PDF file
BNBernard Ng
Bernard Ng
ACAdeline Chu
Adeline Chu
MKMyrna M Khan
Myrna M Khan
Objectives To evaluate the trends in patterns of disease-modifying antirheumatic drugs (DMARDs) and biological agents use from 1999 to 2009 and to identify patient characteristics associated with different patterns of their use in a national sample of Veterans with rheumatoid arthritis (RA). Design A retrospective cohort study. Settings Administrative databases of the USA Department of Veterans Affairs. Participants An incident cohort of 13 254 patients with newly diagnosed RA was identified. Primary outcome measures Trends and choice of DMARDs and biological agents’ usage, and time intervals between RA diagnosis and treatment Results Methotrexate use as first-line agent increased from 39.9% to 57.2% over the study period (p<0.001). Although biological dispensations increased over other DMARDs and biological agents, from 3.4% to 25% from 1999 to 2009, the percentage of RA patients diagnosed between 1999 and 2007 who had biologics dispensations remained steady at 23.3–26.7%. Compared with Caucasian, African Americans were less likely to receive biologics (HR 0.71, 95% CI 0.63 to 0.81). Patients aged 75 and older were less likely to receive biologics than those younger than 45 (HR 0.29, 95% CI 0.23 to 0.36). The time interval between RA diagnosis and treatment with DMARDs and biological agents decreased significantly over time (median: 51 days in 1999–2001 to 28 days in 2006–2007). Conclusions Methotrexate use increased as it became the preferred first-line agent, while other traditional agents declined. Dispensation of biologics increased significantly, but the proportion of RA patients eventually given biologics stabilised below 30%. A significant shorter time between RA diagnosis and DMARD or biological agent initiation in recent years suggests improvements in quality of care. There were disproportionately lower use of biologics in certain age and ethnic groups, and further studies will be needed to elucidate these observations.

27 January 2010 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
AGAlexandra M. Gonzalez-Fuentes
Alexandra M. Gonzalez-Fuentes
DGDavid M. Green
David M. Green
RRRoger D. Rossen
Roger D. Rossen
BNBernard Ng
Bernard Ng

4 September 2014 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ZZZaki Abou Zahr
Zaki Abou Zahr
ASAndrew Spiegelman
Andrew Spiegelman
MCMaria Cantu
Maria Cantu
BNBernard Ng
Bernard Ng